These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39398610)

  • 21. Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab.
    Che YQ; Zhang Y; Wang D; Liu HY; Shen D; Luo Y
    Drug Des Devel Ther; 2019; 13():3727-3734. PubMed ID: 31754298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.
    Kobayashi T; Nishimura M; Hosonaga M; Kizawa R; Kawai S; Aoyama Y; Ozaki Y; Fukada I; Hara F; Takano T; Ueno T
    BMC Cancer; 2024 Sep; 24(1):1156. PubMed ID: 39289642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.
    Luo Y; Zhang X; Mo M; Tan Z; Huang L; Zhou H; Wang C; Wei F; Qiu X; He R; Chen G
    Medicine (Baltimore); 2016 Apr; 95(15):e3337. PubMed ID: 27082587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial.
    Yan H; Yu K; Zhang K; Liu L; Li Y
    Oncotarget; 2017 Nov; 8(60):102458-102467. PubMed ID: 29254261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis.
    Kong YH; Huang JY; Ding Y; Chen SH; Li QS; Xiong Y
    Clin Transl Oncol; 2024 Jul; ():. PubMed ID: 39012453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
    Schettini F; Martínez-Sáez O; Falato C; De Santo I; Conte B; Garcia-Fructuoso I; Gomez-Bravo R; Seguí E; Chic N; Brasó-Maristany F; Paré L; Vidal M; Adamo B; Muñoz M; Pascual T; Ciruelos E; Perou CM; Carey LA; Prat A
    ESMO Open; 2023 Jun; 8(3):101214. PubMed ID: 37075698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
    Leng J; Wu F; Zhang L
    Front Oncol; 2022; 12():734948. PubMed ID: 35651788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab.
    Hong J; Chen X; Gao W; Zhu S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Fei X; Lin L; Shen K
    Cancer Manag Res; 2019; 11():3371-3379. PubMed ID: 31114373
    [No Abstract]   [Full Text] [Related]  

  • 29. The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients.
    Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Tan J; Chen S; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Cancer Res Treat; 2018 Jan; 50(1):19-29. PubMed ID: 28392551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
    Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
    Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
    Chabot I; Zhao Q; Su Y
    Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
    Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
    Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Li Z; Guo F; Han Y; Wang J; Xu B
    Oncol Res Treat; 2022; 45(10):608-617. PubMed ID: 35882206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
    Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.